VolitionRx Limited (VNRX)
NYSEAMERICAN: VNRX · Real-Time Price · USD
0.2470
-0.0129 (-4.96%)
At close: Feb 5, 2026, 4:00 PM EST
0.2450
-0.0020 (-0.81%)
After-hours: Feb 5, 2026, 6:08 PM EST
VolitionRx Revenue
VolitionRx had revenue of $627.28K in the quarter ending September 30, 2025, with 32.19% growth. This brings the company's revenue in the last twelve months to $1.47M, up 14.60% year-over-year. In the year 2024, VolitionRx had annual revenue of $1.23M with 59.10% growth.
Revenue (ttm)
$1.47M
Revenue Growth
+14.60%
P/S Ratio
16.78
Revenue / Employee
$19,627
Employees
75
Market Cap
32.36M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.23M | 458.21K | 59.10% |
| Dec 31, 2023 | 775.30K | 468.91K | 153.04% |
| Dec 31, 2022 | 306.39K | 216.36K | 240.30% |
| Dec 31, 2021 | 90.04K | 76.60K | 570.25% |
| Dec 31, 2020 | 13.43K | -3.66K | -21.43% |
| Dec 31, 2019 | 17.10K | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 54.97K | - | - |
| Dec 31, 2011 | - | - | - |
| Aug 31, 2011 | - | - | - |
| Aug 31, 2010 | - | - | - |
| Aug 31, 2009 | - | - | - |
| Aug 31, 2008 | - | - | - |
| Aug 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TELA Bio | 77.06M |
| Myomo | 41.64M |
| Cytosorbents | 36.98M |
| Baird Medical Investment Holdings | 31.86M |
| electroCore | 29.84M |
| Elutia | 21.75M |
| NeuroOne Medical Technologies | 12.10M |
| IceCure Medical | 2.98M |
VNRX News
- 1 day ago - Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation - PRNewsWire
- 6 days ago - VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays - PRNewsWire
- 9 days ago - Volition Announces Data to Support Use of Nu.Q® NETs in New Indication - PRNewsWire
- 16 days ago - Volition Continues to Extend Access to Nu.Q® Vet Cancer Test - PRNewsWire
- 20 days ago - Volition Sponsors Symposium at Veterinary Meeting and Expo - PRNewsWire
- 4 weeks ago - VolitionRx Secures $2.0 Million in Funding - PRNewsWire
- 4 weeks ago - VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats - PRNewsWire
- 7 weeks ago - Volition Issues Business Review 2025 - PRNewsWire